CluePoints strengthens and expands global team
Written by Patrick Hughes
CluePoints, a leading provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has announced three new appointments to its global team. John Colby and Elizabeth Polvent join the company's U.S business development team, fulfilling a key element in its strategy for growth, while CluePoints also welcomes Jean Stéphenne, President of the Board of Directors of GlaxoSmithKline Biologicals, as a member of its board.
John Colby joins CluePoints as Senior Director of Business Development on the East Coast U.S, providing strategic leadership and driving business growth in the geography. Previously of Aptiv Solutions and PRA International, John brings a strong track record of managing strategic relationships in the clinical trials industry. Elizabeth Polvent has been named as the company's Director of Business Development on the West Coast. Based in California, she has more than 10 years' Clinical Operations experience in the industry with her most recent roles serving as the key liaison on Federally funded clinical trials, as well as overseeing early-phase clinical development programs. She joins CluePoints to support the growth of the business' footprint and to establish long-term partnerships with key customers in the region.
In addition to strengthening its business development team, CluePoints has announced that Jean Stéphenne has joined the company's board of directors. Jean joined SmithKline-RIT (now GSK Biologicals) in 1974 as head of bacterial and viral vaccines production. Through various executive management positions within the company, he has led GSK's global vaccines business since 1988. From March 2010 to April 2012, he was appointed as the Chairman and President of GSK Biologicals. Jean currently serves as a Special Advisor to the CEO at GSK, is a member of the Corporate Executive Team (GSK Group), as well as President of the Board of Directors of GSK Biologicals.
"CluePoints is at a very exciting time in its development with increasing demand for its solutions as a result of growing regulatory support for practical Risk-Based Monitoring techniques," comments Jean Stéphenne. He adds, "With a steadily growing global reputation for delivering scientific excellence and innovation, CluePoints is making its mark on the industry and I am delighted to be joining the company's board and look forward to the opportunity to help build on its achievements."
Franҫois Torche, CEO of CluePoints, comments: "I am delighted to announce the three new additions to our global team. In 2014 CluePoints is focused on fulfilling demand in growing markets and achieving new levels of innovation for customers. I believe the insights and experience of each of these new appointments will be invaluable in our ongoing development."
For further information on CluePoints solutions, please visit www.cluepoints.com
CluePoints® is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA and EMA, CluePoints® is deployed to support traditional on-site monitoring and can be implemented as the engine to drive a Risk-Based Monitoring strategy. The value of using CluePoints® lies in its powerful and timely ability to identify anomalous data and site errors allowing improvement in clinical data quality, optimisation of on-site monitoring and a significant reduction in overall regulatory submission risk.
Birdie aims to reinvent elderly care with tech
British startup Birdie has announced it has raised £8.2 million to invest in innovation and scale up the business.
The company's announcement is timely as it follows the criticism of the UK government over their lack of a plan for social care, despite acknowledging the sector is in crisis - around a quarter of the UK's home care providers are on the brink of bankruptcy due to a lack of funds and staffing.
Birdie was born with a mission to "radically improve the lives of millions of older adults", by using app-based solutions, IoT and machine learning to put preventative care at the forefront. The company was founded by Max Parmentier, after experiencing his own frustrations with the care system - his grandfather struggled with the impact of life in a care home, but lacked any other option.
In 2017 Parmentier partnered with venture builder Kamet Ventures to set up Birdie, in a bid to fix this problem. Since then, Birdie has partnered with almost 500 providers across the UK, and supports more than 20,000 older people every week. In the past 12 months alone the number of people Birdie supports has got six times greater.
Birdie’s solution is an app to help care providers deliver more coordinated, personalised and preventative care, by giving them access to digital assessments, medication scheduling and planning tools. By using digital tools to take care of admin, staff have more time to spend with their care recipients.
The new investment will be used to fund Birdie’s next phase of growth in the UK, as the company scales to meet the rapidly growing demand of the aging population. The company will also invest in product innovation, creating new features to address customer requests.
In addition, Birdie is piloting new care models, including partnering with the NHS to identify COVID-19 symptoms, building predictive pharmacy models with AI, and helping health authorities to detect early warning signs of patients’ health risks.
Internally, Birdie is committed to having a progressive company ethos. All salaries are transparent, and staff work asynchronously to maximise flexibility and equity. Staff members also volunteer in their local community during office hours, and the company offsets all its emissions.
These efforts have led to numerous awards, including having the best SME culture in the UK, an Honorable Mention in the Health category of Fast Company’s 2021 World Changing Ideas Awards, and innovation in care at the LangBuisson awards.
“We believe the future of care for older people should be helping them to live at home for as long as possible through the delivery of personalised and preventative care" Parmentier said.
"Birdie is already the partner of choice for caregivers up and down the UK, and this new funding will help us rapidly increase the number we partner with and what we can offer them - meaning more people benefiting from more affordable, quality care. We’re proud of our mission and the values we embody to pursue it.”